Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Fate Therapeutics, Inc.
  6. Summary
    FATE   US31189P1021

FATE THERAPEUTICS, INC.

(FATE)
  Report
Delayed Nasdaq  -  04:00:00 2023-03-24 pm EDT
5.390 USD   +3.06%
03/14Transcript : Fate Therapeutics, Inc. Presents at Barclays Global Healthcare Conference, Mar-14-2023 03:05 PM
CI
03/06Fate Therapeutics to Present at Upcoming March Investor Conferences
AQ
03/03Fate Therapeutics to Present at Upcoming March Investor Conferences
GL
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/20/2023 03/21/2023 03/22/2023 03/23/2023 03/24/2023 Date
5.56(c) 5.42(c) 5.15(c) 5.23(c) 5.39 Last
3 031 589 1 679 472 2 765 006 2 140 561 1 708 987 Volume
+0.36% -2.52% -4.98% +1.55% +3.06% Change
More quotes
Estimated financial data (e) (USD)
Sales 2023 50,1 M - -
Net income 2023 -218 M - -
Net cash position 2023 205 M - -
P/E ratio 2023 -2,56x
Yield 2023 -
Sales 2024 23,6 M - -
Net income 2024 -173 M - -
Net Debt 2024 4,40 M - -
P/E ratio 2024 -3,40x
Yield 2024 -
Capitalization 529 M 529 M -
EV / Sales 2023 6,48x
EV / Sales 2024 22,6x
Nbr of Employees 551
Free-Float 97,5%
More Financials
Company
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of programmed cellular immunotherapies for patients with cancer. It uses human induced pluripotent stem cells (iPSCs) generated from its proprietary iPSC product platform to create genetically engineered, clonal master iPSC lines having preferred biological properties. The Company is advancing a pipeline... 
Read more
More about the company
Ratings of Fate Therapeutics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about FATE THERAPEUTICS, INC.
03/14Transcript : Fate Therapeutics, Inc. Presents at Barclays Global Healthcare C..
CI
03/06Fate Therapeutics to Present at Upcoming March Investor Conferences
AQ
03/03Fate Therapeutics to Present at Upcoming March Investor Conferences
GL
03/02Citigroup Adjusts Fate Therapeutics Price Target to $10 From $9, Maintains Buy Rating
MT
02/28Transcript : Fate Therapeutics, Inc., Q4 2022 Earnings Call, Feb 28, 2023
CI
02/28Fate Therapeutics : Q4 Earnings Snapshot
AQ
02/28FATE THERAPEUTICS INC Management's Discussion and Analysis of Financial Condition and ..
AQ
02/28Fate Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2..
CI
02/28Earnings Flash (FATE) FATE THERAPEUTICS Reports Q4 Revenue $44.4M
MT
02/28Fate Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December ..
CI
02/28Fate Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Busin..
GL
02/13Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 202..
GL
02/13Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 202..
GL
01/25North American Morning Briefing: Microsoft -2-
DJ
01/24HC Wainwright Downgrades Fate Therapeutics to Neutral From Buy, Adjusts Price Target to..
MT
More news
News in other languages on FATE THERAPEUTICS, INC.
02/28Fate Therapeutics, Inc. annonce ses résultats pour l'année complète se terminant le 31 ..
02/28Fate Therapeutics, Inc. annonce ses résultats pour le quatrième trimestre clos le 31 dé..
02/17BB Biotech bestätigt Verlust für 2022 - Erwartet mehr Aktivität 2023
01/06Les plans de priorisation du pipeline de Century Therapeutics indiquent un déclin de l'..
01/06Principales baisses à la mi-journée
More news
Analyst Recommendations on FATE THERAPEUTICS, INC.
More recommendations
ETFs positioned on FATE THERAPEUTICS, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
Loncar Cancer Immunotherapy ETF - USD1.37%-5.65%-World
IShares Genomics Immunology and Healthcare ...1.02%-2.96%World
CI Bio-Revolution ETF - CAD0.42%0.00%-NC
Global X Guru Index ETF - USD0.32%-1.75%United_States
Virtus LifeSci Biotech Clinical Trials ETF - USD0.28%-7.05%United_States
More ETFs positioned on FATE THERAPEUTICS, INC.
Chart FATE THERAPEUTICS, INC.
Duration : Period :
Fate Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FATE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 5,39 $
Average target price 8,27 $
Spread / Average Target 53,3%
EPS Revisions
Managers and Directors
J. Scott Wolchko President CEO, CFO & Director
Edward J. Dulac Chief Financial Officer & Accounting Officer
William H. Rastetter Chairman
Wen Bo Wang Senior Vice President-Technical Operations
Bahram Valamehr Chief Research & Development Officer
Sector and Competitors
1st jan.Capi. (M$)
FATE THERAPEUTICS, INC.-48.17%513
REGENERON PHARMACEUTICALS, INC.11.18%85 611
VERTEX PHARMACEUTICALS5.53%78 349
WUXI APPTEC CO., LTD.-1.06%34 400
BIONTECH SE-13.87%31 444
GENMAB A/S-13.29%24 332
1 MarketScreener is worth more than 1000 Influencers!
100% Free Registration
fermer